Literature DB >> 1347270

Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis.

K Fuxe1, A M Janson, L Rosén, U B Finnman, S Tanganelli, M Morari, M Goldstein, L F Agnati.   

Abstract

Based on the observations that the psychostimulant drug amphetamine in combination with physiotherapy can promote recovery of brain function after brain injury, we have studied the ability of the vigilance promoting drug Modafinil to counteract 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-(MPTP)-induced degeneration of the nigrostriatal dopamine (DA) neurons of the black mouse. MPTP was given s.c. in a dose of 40 mg/kg and the mice were sacrificed 2 weeks later. The effects of acute and chronic treatment with Modafinil were studied on MPTP-induced DA neurotoxicity. The substantia nigra and neostriatum were taken to both biochemical and histochemical analysis of presynaptic parameters of the nigrostriatal DA neurons, the latter in combination with image analysis. In separate experiments in rats in vivo tests for DA uptake blocking activity were made using intrastriatal microdialysis to study superfusate levels of DA and its metabolites and the 4-alpha-dimethylmetatyramine (H77/77) model to test for a possible ability of Modafinil to protect against H77/77-induced depletion of forebrain DA stores. Chronic treatment with Modafinil in doses of 10 to 100 mg/kg counteracted the MPTP-induced disappearance of nigral TH IR nerve cell body profiles and neostriatal TH IR nerve terminal profiles as evaluated after 2 weeks with image analysis. Chronic treatment with Modafinil (10-100 mg/kg) also dose-dependently counteracted the MPTP-induced disappearance of striatal DA uptake binding sites as evaluated at the same time interval. Also in the dose range 10-100 mg/kg Modafinil counteracts the MPTP-induced depletion of DA stores both in the neostriatum and the substantia nigra. In the acute experiments Modafinil (30 mg/kg) protected against the MPTP-induced depletion of striatal DA, dihydrophenylacetic acid (DOPAC) and homovanillic acid (HVA) levels both when given 15 min before, at the same time and 3 h following the MPTP injection. In the substantia nigra, however, these protective actions of Modafinil were only observed when the drug was coadministered with MPTP. Experiments with microdialysis in intact rats failed to demonstrate any increases of superfusate DA levels in neostriatum with 30 mg/kg of Modafinil. Modafinil in high doses of 2 x 50 mg/kg, however, significantly counteracted the H77/77 induced DA depletion of striatal DA stores. Thus, morphological and biochemical evidence has been obtained that Modafinil in the dose range 10-100 mg/kg protects against MPTP-induced degeneration of the nigrostriatal DA neurons of the black mouse.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1347270     DOI: 10.1007/bf02259133

Source DB:  PubMed          Journal:  Exp Brain Res        ISSN: 0014-4819            Impact factor:   1.972


  28 in total

1.  Effects of cholecystokinin peptides and neurotensin on dopamine release and metabolism in the rostral and caudal part of the nucleus accumbens using intracerebral dialysis in the anaesthetized rat.

Authors:  M Ruggeri; U Ungerstedt; L F Agnati; V Mutt; A Härfstrand; K Fuxe
Journal:  Neurochem Int       Date:  1987       Impact factor: 3.921

2.  Chronic nicotine treatment counteracts the disappearance of tyrosine-hydroxylase-immunoreactive nerve cell bodies, dendrites and terminals in the mesostriatal dopamine system of the male rat after partial hemitransection.

Authors:  A M Janson; K Fuxe; L F Agnati; I Kitayama; A Härfstrand; K Andersson; M Goldstein
Journal:  Brain Res       Date:  1988-07-12       Impact factor: 3.252

Review 3.  Pharmacotherapy for recovery of function after brain injury.

Authors:  D M Feeney; R L Sutton
Journal:  Crit Rev Neurobiol       Date:  1987

4.  Effects of some antidepressant drugs on the depletion of intraneuronal brain catecholamine stores caused by 4,alpha-dimethyl-meta-tyramine.

Authors:  A Carlsson; H Corrodi; K Fuxe; T Hökfelt
Journal:  Eur J Pharmacol       Date:  1969-03       Impact factor: 4.432

5.  Purification and characterization of tyrosine hydroxylase from a clonal pheochromocytoma cell line.

Authors:  K A Markey; H Kondo; L Shenkman; M Goldstein
Journal:  Mol Pharmacol       Date:  1980-01       Impact factor: 4.436

6.  GM1 ganglioside-induced recovery of nigrostriatal dopaminergic neurons after MPTP: an immunohistochemical study.

Authors:  M Hadjiconstantinou; A P Mariani; N H Neff
Journal:  Brain Res       Date:  1989-04-10       Impact factor: 3.252

7.  Chronic Parkinsonism secondary to intravenous injection of meperidine analogues.

Authors:  G C Davis; A C Williams; S P Markey; M H Ebert; E D Caine; C M Reichert; I J Kopin
Journal:  Psychiatry Res       Date:  1979-12       Impact factor: 3.222

8.  Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice.

Authors:  R E Heikkila; A Hess; R C Duvoisin
Journal:  Science       Date:  1984-06-29       Impact factor: 47.728

9.  Pharmacological interference with the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in the mouse.

Authors:  E Sundström; G Jonsson
Journal:  Eur J Pharmacol       Date:  1985-04-16       Impact factor: 4.432

10.  Administration of GM1 ganglioside restores the dopamine content in striatum after chronic treatment with MPTP.

Authors:  M Hadjiconstantinou; Z L Rossetti; R C Paxton; N H Neff
Journal:  Neuropharmacology       Date:  1986-09       Impact factor: 5.250

View more
  13 in total

1.  Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents.

Authors:  Neil E Paterson; Allison Fedolak; Berend Olivier; Taleen Hanania; Afshin Ghavami; Barbara Caldarone
Journal:  Pharmacol Biochem Behav       Date:  2010-03-25       Impact factor: 3.533

Review 2.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

3.  Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil.

Authors:  L H Gold; R L Balster
Journal:  Psychopharmacology (Berl)       Date:  1996-08       Impact factor: 4.530

Review 4.  Modafinil : a review of its use in excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome and shift work sleep disorder.

Authors:  Gillian M Keating; Michael J Raffin
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

5.  Wake-promoting agent modafinil worsened attentional performance following REM sleep deprivation in a young-adult rat model of 5-choice serial reaction time task.

Authors:  Yia-Ping Liu; Che-Se Tung; Yu-Lung Lin; Chia-Hsin Chuang
Journal:  Psychopharmacology (Berl)       Date:  2010-09-24       Impact factor: 4.530

Review 6.  Drug treatment of patients with insomnia and excessive daytime sleepiness: pharmacokinetic considerations.

Authors:  S Nishino; E Mignot
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

7.  Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Authors:  S K Kidd; J S Schneider
Journal:  Neuroscience       Date:  2011-08-06       Impact factor: 3.590

8.  Neuroprotective effect of ethanol and Modafinil on focal cerebral ischemia in rats.

Authors:  Yusef Abbasi; Ronak Shabani; Kazem Mousavizadeh; Mansoureh Soleimani; Mehdi Mehdizadeh
Journal:  Metab Brain Dis       Date:  2019-01-15       Impact factor: 3.584

9.  Modafinil : A Review of its Pharmacology and Clinical Efficacy in the Management of Narcolepsy.

Authors:  K J McClellan; C M Spencer
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

10.  The vigilance-promoting drug modafinil counteracts the reduction of tyrosine hydroxylase immunoreactivity and of dopamine stores in nigrostriatal dopamine neurons in the male rat after a partial transection of the dopamine pathway.

Authors:  A Ueki; L Rosén; B Andbjer; U B Finnman; U Altamimi; A M Janson; M Goldstein; L F Agnati; K Fuxe
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.